Patent US4849209A successfully refreshed from Google Patents.
US4849209A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
Assignee: Cordis Corp
•
Filing: 1987-01-28
•
Granted: 1989-07-18
•
Expires: 2007-01-28
Abstract
Abstract 1/3 Holmium in a carrier metallic hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis. The compound disclosed preferably has a particle size of 1 to 40 microns, Beta energy emissions in the range of 1.76-1.84 MeV, low levels of gamma ray emissions and a radioactive half-life of 26.8 hours. The preferred metallic hydroxide is selected from the group consisting of Ferric Hydroxide, Aluminum Hydroxide, Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Hydroxide. Methods are also disclosed for the preparation of the compound, as well as for the methods of its administration to a patient in need thereof.
Inventors
- 👤 Ephraim Lieberman
- 👤 Maurice Bordoni
- 👤 Alfred Thornton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 12:30
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1217; A61K2121/00
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and a ferric hydroxide aggregate.
Claim 2
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and a ferric hydroxide aggregate.
Claim 3
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and an aluminum hydroxide aggregate.
Claim 4
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and an aluminum hydroxide aggregate.
Claim 5
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and a metallic hydroxide aggregate.
Claim 6
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and a metallic hydroxide aggregate.
Claim 7
Dependent Claim
33 words
The composition of claim 3, wherein the metallic hydroxide aggregate component is a transition metallic hydroxide selected from the group consisting of Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Hydroxide.
Claim 8
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and a metallic hydroxide macroaggregate.
Claim 9
Dependent Claim
30 words
A radioactive composition for the treatment of rheumatoid arthritis comprising an aggregated suspension containing particles having a minimum size of one micron including 166 Holmium and a metallic hydroxide macroaggregate.
Claim 10
Dependent Claim
14 words
The compound of claim 5, wherein the aggregated suspension contains a ferric hydroxide macroaggregate.
Claim 11
Dependent Claim
14 words
The composition of claim 5, wherein the aggregated suspension contains an aluminum hydroxide macroaggregate.
Claim 12
Dependent Claim
32 words
The composition of claim 5, wherein the metallic hydroxide macroaggregate is a transition metallic hydroxide selected from the group consisting of Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Hydroxide.
Claim 13
Dependent Claim
27 words
A radioactive composition for the treatment of arthritis comprising 166 Holmium Hydroxide in a carrier ferric hydroxide aggregate containing particles having a minimum size of one micron.
Claim 14
Dependent Claim
27 words
A radioactive composition for the treatment of arthritis comprising 166 Holmium Hydroxide in a carrier ferric hydroxide aggregate containing particles having a minimum size of one micron.
Claim 15
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier ferric hydroxide aggregate containing particles having a minimum size of one micron.
Claim 16
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier ferric hydroxide aggregate containing particles having a minimum size of one micron.
Claim 17
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier ferric hydroxide macroaggregate containing particles having a minimum size of one micron.
Claim 18
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier ferric hydroxide macroaggregate containing particles having a minimum size of one micron.
Claim 19
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier aluminum hydroxide aggregate containing particles having a minimum size of one micron.
Claim 20
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier aluminum hydroxide aggregate containing particles having a minimum size of one micron.
Claim 21
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier aluminum hydroxide macroaggregate containing particles having a minimum size of one micron.
Claim 22
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier aluminum hydroxide macroaggregate containing particles having a minimum size of one micron.
Claim 23
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier metallic hydroxide aggregate containing particles having a minimum size of one micron.
Claim 24
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier metallic hydroxide aggregate containing particles having a minimum size of one micron.
Claim 25
Dependent Claim
33 words
The composition of claim 14, wherein the carrier metallic hydroxide aggregate is a transition metallic hydroxide selected from the group consisting of Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide, and Stannous Hydroxide.
Claim 26
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier metallic hydroxide macroaggregate containing particles having a minimum size of one micron.
Claim 27
Dependent Claim
28 words
A radioactive composition for the treatment of rheumatoid arthritis comprising 166 Holmium Hydroxide in a carrier metallic hydroxide macroaggregate containing particles having a minimum size of one micron.
Claim 28
Dependent Claim
33 words
The composition of claim 16, wherein the carrier metallic hydroxide macroaggregate is a transition metallic hydroxide selected from the group consisting of Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Chloride.
Claim 29
Dependent Claim
47 words
A radioactive composition for the treatment of arthritis comprising 166 Holmium in a carrier metallic hydroxide aggregate having a particle size of from 1 micron-40 microns, Beta energy emissions substantially in the range of 1.76-1.84 MeV, low levels of gamma emissions and a half-life of 26.8 hours.
Claim 30
Dependent Claim
47 words
A radioactive composition for the treatment of arthritis comprising 166 Holmium in a carrier metallic hydroxide aggregate having a particle size of from 1 micron-40 microns, Beta energy emissions substantially in the range of 1.76-1.84 MeV, low levels of gamma emissions and a half-life of 26.8 hours.
Claim 31
Dependent Claim
32 words
A radioactive composition comprising, in combination, a ferric hydroxide or aluminum hydroxide aggregate suspension having a particle size greater than 1 micron, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 32
Dependent Claim
32 words
A radioactive composition comprising, in combination, a ferric hydroxide or aluminum hydroxide aggregate suspension having a particle size greater than 1 micron, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 33
Dependent Claim
64 words
A radioactive composition for the treatment of arthritis comprising a radionuclide compound entrapped in an aggregate, wherein the aggregate is a ferric hydroxide aggregate or an aluminum hydroxide aggregate, the composition having a size of 1-20 microns and wherein the radionuclide compound is 166 Holmium, thereby facilitating preparation of the compound at a central location and delivery of the same through available transportation channels.
Claim 34
Dependent Claim
64 words
A radioactive composition for the treatment of arthritis comprising a radionuclide compound entrapped in an aggregate, wherein the aggregate is a ferric hydroxide aggregate or an aluminum hydroxide aggregate, the composition having a size of 1-20 microns and wherein the radionuclide compound is 166 Holmium, thereby facilitating preparation of the compound at a central location and delivery of the same through available transportation channels.
Claim 35
Dependent Claim
37 words
A radioactive composition for the treatment of arthritis comprising, in combination, a ferric hydroxide or aluminum hydroxide aggregate suspension having a particle size greater than 3 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 36
Dependent Claim
37 words
A radioactive composition for the treatment of arthritis comprising, in combination, a ferric hydroxide or aluminum hydroxide aggregate suspension having a particle size greater than 3 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 37
Dependent Claim
29 words
A radioactive composition comprising, in combination, a metal hydroxide aggregate suspension having a particle size greater than 1 micron, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 38
Dependent Claim
29 words
A radioactive composition comprising, in combination, a metal hydroxide aggregate suspension having a particle size greater than 1 micron, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-17 | 1993-01-16 | 1993-07-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-17 | 1997-01-16 | 1997-07-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-17 | 2001-01-16 | 2001-07-18 | $7700.00 | Window Closed / Lapsed |